>
Celgene logo

CELG - Celgene Share Price

$108.24 0.1  0.1%

Last Trade - 20/11/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £12.31bn
Position in Universe th / 7242
Bullish
Bearish
Unlock CELG Revenue
Momentum
Relative Strength (%)
1m +2.02%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
6,494 7,670 9,256 11,229 13,003 15,281 17,486 19,041 +18.7%
+2.2 +31.7 -10.3 +31.9 +25.4 +53.8 +97.7 +10.5
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2019, CelgeneCorporation revenues increased 15% to $12.95B. Net incomebefore extraordinary items increased 60% to $4.81B.Revenues reflect Foreign exchange contracts increase from-$24M to $65M. Net income benefited from Research anddevelopment -Other decrease of 22% to $3.16B (expense),Stock-based Compensation in R&D decrease of 32% to $326M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CELG Revenue Unlock CELG Revenue

Net Income

CELG Net Income Unlock CELG Revenue

Normalised EPS

CELG Normalised EPS Unlock CELG Revenue

PE Ratio Range

CELG PE Ratio Range Unlock CELG Revenue

Dividend Yield Range

CELG Dividend Yield Range Unlock CELG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CELG EPS Forecasts Unlock CELG Revenue
Profile Summary

Celgene Corporation is a United States-based biopharmaceutical company. The Company is primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. It develops the medicines to treat patients with rare diseases and diseases of unmet medical need. The Company’s medical Canadian trials include Multiple Myeloma (MM), Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML), Beta-Thalassemia, Atopic Dermatitis, Psoriatic Arthritis, Psoriasis, Ulcerative Colitis, Crohn’s Disease and Multiple Sclerosis.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated April 17, 1986
Public Since July 1, 1987
No. of Shareholders: 360
No. of Employees: 8,852
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Global 100,
Exchange NASDAQ Global Select Market
Shares in Issue 711,400,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CELG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CELG
Upcoming Events for CELG
Frequently Asked Questions for Celgene
What is the Celgene share price?

As of 20/11/19, shares in Celgene are trading at $108.24, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Celgene share price performed this year?

Shares in Celgene are currently trading at $108.24 and the price has moved by 55.81% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Celgene price has moved by 19.57% over the past year.

What are the analyst and broker recommendations for Celgene?

Of the analysts with advisory recommendations for Celgene, there are there are currently 0 "buy" , 15 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Celgene is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Celgene next release its financial results?

Celgene is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-09-30
What is the Celgene dividend yield?

Celgene does not currently pay a dividend.

Does Celgene pay a dividend?

Celgene does not currently pay a dividend.

When does Celgene next pay dividends?

Celgene does not currently pay a dividend.

How do I buy Celgene shares?

To buy shares in Celgene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Celgene?

Shares in Celgene are currently trading at $108.24, giving the company a market capitalisation of £n/a.

Where are Celgene shares listed? Where are Celgene shares listed?

Here are the trading details for Celgene:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: CELG
What kind of share is Celgene?

We were not able to load our ranking data for Celgene

Is there a Celgene share price forecast 2021?

We were not able to load any forecast data for Celgene.

How can I tell whether the Celgene share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celgene. Over the past six months, the relative strength of its shares against the market has been 5.35%. At the current price of $108.24, shares in Celgene are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Celgene PE Ratio?

We were not able to find PE ratio data for Celgene.

Who are the key directors of Celgene?

We were unable to find the directors for Celgene.

Who are the major shareholders of Celgene?

Here are the top five shareholders of Celgene based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.71% (54.9m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.28% (37.6m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.19% (29.8m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.79% (19.9m shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 2.18% (15.5m shares)
Similar to CELG
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.